Emyria Recruits First Patient MDMA-Assisted Therapy Trial

The EMDMA-001 trial serves several strategic purposes for Emyria.

First and foremost, it gives our psychiatrists invaluable experience in administering MDMA-assisted therapy, a prerequisite for obtaining Authorised Prescriber status. This status is essential for us to offer these novel treatments to patients on a user-pays basis.

Moreover, the extensive data we collect from this trial will not only support evaluations of efficacy and safety of MDMA-assisted therapy, but it will also aids a robust cost-benefit analysis. At an estimated cost of $25,000 per full treatment cycle, these therapies represent a substantial investment for patients. Strong evidence of their value will be vital for convincing payers to cover these costs, making treatment more accessible and scalable.

Finally, the trial represents another step in establishing Emyria as a leader in the development and delivery of psychedelic-assisted mental health treatments. This positions us advantageously in a rapidly growing and evolving market, further enticing potential investors.

In summary, the EMDMA-001 trial is a crucial component in Emyria's strategic plan, poised to catalyse our growth, enhance our credibility, and ultimately drive our mission of providing cutting-edge mental health treatments to those who need them most.